Table 1.
Completed clinical trials (Clinicaltrials.gov, accession date: March 1, 2023)
|
Method
|
Intervention
|
Trial number
|
Phase
|
Title
|
Condition
|
| Biological | Peginterferon alfa-2b (SCH 54031) | NCT00049842 | 3 | Prevention of Disease Progress in Chronic Hepatitis C Patients with Liver Fibrosis (Study P02570AM2) | Chronic HCV; Liver fibrosis |
| PegIntron (peginterferon alfa-2b; SCH 54031) REBETOL (ribavirin; SCH 18908) | NCT00039871 | 3 | PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370) | Hepatitis; HCV; Fibrosis; Liver cirrhosis | |
| Simtuzumab | NCT01707472 | 2 | Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults with Liver Fibrosis | Liver fibrosis; HCV infection; HIV | |
| Simtuzumab | NCT01672853 | 2 | Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults with PSC | PSC | |
| Dietary regulation | GK#10; Placebo | NCT01598064 | N/A | Probiotics for Liver Cirrhosis with Portal Hypertension | Liver cirrhosis; Portal hypertension |
| Drug | Aramchol | NCT02279524 | 2 | A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH | Fatty liver; NASH; Liver fibrosis |
| BI 201335 | NCT01909778 | 1 | Open Label Single Dose Phase I Trial of BI 201335 to Study Pharmacokinetics and Safety in Patients with Compensated Liver Cirrhosis | HCV; Liver cirrhosis | |
| BMS-986036; Placebo | NCT03486912 | 2 | A Study of Experimental Medication BMS-986036 in Adults with NASH and Liver Cirrhosis | Hepatic cirrhosis; Liver fibrosis; NAFLD; NASH | |
| BMS-98603; Other: Placebo | NCT03486899 | 2 | A Study of Experimental Medication BMS-986036 in Adults with NASH and Stage 3 Liver Fibrosis | Liver fibrosis; NAFLD; NASH | |
| BMS-986263 placebo | NCT03420768 | 2 | A Study of Experimental Medication BMS-986263 in Adults with Advanced Hepatic Fibrosis After Cure of Hepatitis C | Hepatic cirrhosis; Liver fibrosis | |
| Cenicriviroc placebo | NCT02217475 | 2 | Efficacy and Safety Study of Cenicriviroc for the Treatment of NASH in Adult Participants with Liver Fibrosis | NASH | |
| CRV431 placebo | NCT04480710 | 2 | A Study of CRV431 Dosed Once Daily in NASH-induced F2 and F3 Subjects | NASH; Fibrosis; NAFLD | |
| Fuzheng Huayu placebo | NCT00854087 | 2 | Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients with Hepatic Fibrosis | Chronic HCV | |
| GI262570 placebo | NCT00244751 | 2 | Antifibrotic Activity of GI262570 In Chronic Hepatitis C Subjects | Cirrhosis, liver | |
| GR-MD-02 placebo | NCT02462967 | 2 | Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients with Nash Cirrhosis | Hypertension, portal | |
| GR-MD-02; Placebo | NCT02421094 | 2 | Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients with NASH With Advanced Fibrosis | NASH | |
| IDN-6556; Placebo | NCT02230670 | 2 | A Study of IDN-6556 in Subjects with Liver Cirrhosis | Liver cirrhosis; Hepatic cirrhosis | |
| IDN-6556; Placebo | NCT02138253 | 2 | A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV | Liver fibrosis; Liver cirrhosis | |
| INT-747; Ursodeoxycholic acid; Placebo | NCT00550862 | 2 | Study of INT 747 in Combination with URSO in Patients with PBC | Liver cirrhosis; Biliary injury | |
| Nitazoxanide; BID | NCT03656068 | 2 | An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients with Fibrosis | NASH; Fatty liver; Fibrosis; Compensated cirrhosis | |
| Placebo obeticholic acid | NCT00570765 | 2 | Study of INT-747 as Monotherapy in Participants with PBC | Liver cirrhosis, biliary injury | |
| SEL; Simtuzumab | NCT02466516 | 2 | Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination with Simtuzumab in Adults with NASH and Fibrosis Stages F2-F3 | NASH | |
| Simeprevir; Daclatasvir; Sofosbuvir | NCT02349048 | 2 | Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants with Chronic HCV Genotype 1 Infection | HCV | |
| Tropifexor (LJN452) CVC | NCT03517540 | 2 | Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients with NASH and Liver Fibrosis | NASH | |
| Peginterferon alfa-2a + Ribavirin; Peginterferon alfa-2a | NCT00006164 | 3 | Long Term Interferon for Patients Who Did Not Clear HCV with Standard Treatment | Chronic HCV; Cirrhosis; Fibrosis; Hepatic cirrhosis | |
| OMACOR placebo oral capsule | NCT00760513 | 4 | Treatment of non-Alcoholic Fatty Liver Disease With n-3 Fatty Acids | NAFLD | |
| Ceftriaxone normal saline | NCT04218695 | 4 | Prophylactic Antibiotics in Admitted Cirrhotics | Cirrhosis, LIVER | |
| Proton pump inhibitors placebo | NCT03175731 | 4 | PPIs and Gastroesophageal Varices in Liver Cirrhosis (PPIs: Proton pump inhibitors) | Liver cirrhosis; Hypertension, portal | |
| Other | Human fetal liver cell transplantation | NCT01013194 | 1 or 2 | Human Fetal Liver Cell Transplantation in Chronic Liver Failure | Liver cirrhosis |
| G-colony stimulating factor and infusion of the mobilized monocyte cells | NCT01503749 | 1 | Safety and Efficacy Study of Peripheral Blood Mononucleated Cells for Treatment of Liver Cirrhosis | Liver cirrhosis | |
| Leukapheresis; Infusion of stem cells via image-guided scan | NCT00147043 | N/A | Adult Stem Cell Therapy in Liver Insufficiency | Liver cirrhosis |
N/A: Not applicable; CVC: Cenicriviroc; HCV: Hepatitis C virus; HIV: Human immunodeficiency virus; NAFLD: non-alcoholic fatty liver disease; NASH: Nonalcoholic steatohepatitis; PBC: Primary biliary cirrhosis; PSC: Primary sclerosing cholangitis.